JBJI Journal of Bone and Joint Infection JBJI J. Bone Joint Infect. 2206-3552 Ivyspring Göttingen, Germany 10.7150/jbji.35683 A population-based study on the treatment and outcome of enterococcal prosthetic joint infections. A consecutive series of 55 cases Thompson Olof 1 Rasmussen Magnus 1 Stefánsdóttir Anna 2 Christensson Bertil 1 Åkesson Per 1 Lund University, Department of Clinical Sciences Lund, Division of Infection Medicine and Skåne University Hospital, Department of Infectious Diseases, Lund, Sweden; Lund University, Department of Clinical Sciences Lund, Division of Orthopedics and Skåne University Hospital, Department of Orthopedics, Lund, Sweden. 07 11 2019 4 6 285 291 Copyright: © 2019 Olof Thompson et al. 2019 This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this licence, visit https://creativecommons.org/licenses/by/4.0/ This article is available from https://jbji.copernicus.org/articles/4/285/2019/jbji-4-285-2019.html The full text article is available as a PDF file from https://jbji.copernicus.org/articles/4/285/2019/jbji-4-285-2019.pdf

<p class="p p-first" id="__p2">AIM: Enterococci cause 2-11% of all prosthetic joint infections (PJI) and are generally considered difficult to treat. However, study-results are not consistent. In this study we present a population-based case series of 55 cases with enterococcal PJI, investigating treatment and outcome, as well as describing the affected patient population regarding demography and co-morbidities.</p><p id="__p3">METHODS: We identified all enterococcal PJIs in the Region of Skåne, Sweden, during a five-year period (2011-2015) and reviewed the patients' medical records.</p><p id="__p4">RESULTS: Fifty-five enterococcal PJIs were found. Enterococcus faecalis was the most frequently isolated species (84%), and poly-microbial infections were common (64%). Treatment with intention to cure was given to 43 (78%) cases. Debridement with retention of the implant and antibiotics (DAIR) was the most common surgical treatment strategy (71%), with a cure-rate of 72%. Overall cure-rate was 67%, and in cases where cure was intended, this was achieved in 80%.</p><p class="p p-last" id="__p5">CONCLUSIONS: When cure is aimed for, the prognosis for enterococcal PJI is not so poor, and DAIR treatment can provide adequate results in many cases.</p>

 References Stefánsdóttir A, Johansson D, Knutson K, Lidgren L, Robertsson O. Microbiology of the infected knee arthroplasty: Report from the Swedish Knee Arthroplasty Register on 426 surgically revised cases. Scand J Infect Dis; 2009. p. 41. (11/12):831-840. doi:10.3109/00365540903186207. Lindberg-Larsen M, Pitter FT, Voldstedlund M, Schrøder HM, Bagger J. Microbiological diagnosis in revision of infected knee arthroplasties in Denmark. Infect Dis (Auckl) 2017;49(11-12):824–830. doi:10.1080/23744235.2017.1350878. Zimmerli W, Sendi P. Orthopaedic biofilm infections. APMIS. 2017;125(4):353–364. doi:10.1111/apm.12687. Moran E, Masters S, Berendt AR, McLardy-Smith P, Byren I, Atkins BL. Guiding empirical antibiotic therapy in orthopaedics: The microbiology of prosthetic joint infection managed by debridement, irrigation and prosthesis retention. J Infect. 2007;55(1):1–7. doi:10.1016/j.jinf.2007.01.007. Osmon DR, Berbari EF, Berendt AR. et al. Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2013;56(1):e1–e25. doi:10.1093/cid/cis803. Sandoe JAT, Wysome J, West AP, Heritage J, Wilcox MH. Measurement of ampicillin, vancomycin, linezolid and gentamicin activity against enterococcal biofilms. J Antimicrob Chemother. 2006;57(4):767–770. doi:10.1093/jac/dkl013. Tornero E, Senneville E, Euba G. et al. Characteristics of prosthetic joint infections due to Enterococcus sp. and predictors of failure: A multi-national study. Clin Microbiol Infect. 2014;20(11):1219–1224. doi:10.1111/1469-0691.12721. Sandoe JAT, Witherden IR, Cove JH, Heritage J, Wilcox MH. Correlation between enterococcal biofilm formation in vitro and medical-device-related infection potential in vivo. J Med Microbiol. 2003;52(7):547–550. doi:10.1099/jmm.0.05201-0. Holmberg A, Thórhallsdóttir VG, Robertsson O, W-Dahl A, Stefánsdóttir A. 75% success rate after open debridement, exchange of tibial insert, and antibiotics in knee prosthetic joint infections. Acta Orthop. 2015;86(4):457–462. doi:10.3109/17453674.2015.1026756. [PMC free article] Lam A, Rasmussen M, Thompson O. Successful outcome for patients with streptococcal prosthetic joint infections - a retrospective population-based study. Infect Dis (Auckl) 2018;50(8):593–600. doi:10.1080/23744235.2018.1449961. Zimmerli W, Trampuz A, Ochsner PE. Prosthetic-joint infections. N Engl J Med. 2004;351(16):1645–1654. doi:10.1056/NEJMra040181. Rasouli MR, Tripathi MS, Kenyon R, Wetters N, Della Valle CJ, Parvizi J. Low rate of infection control in enterococcal periprosthetic joint infections infection. Clin Orthop Relat Res. 2012;470(10):2708–2716. doi:10.1007/s11999-012-2374-8. [PMC free article] El Helou OC, Berbari EF, Marculescu CE. et al. Outcome of Enterococcal Prosthetic Joint Infection: Is Combination Systemic Therapy Superior to Monotherapy? Clin Infect Dis. 2008;47(7):903–909. doi:10.1086/591536. Kheir MM, Tan TL, Higuera C. et al. Periprosthetic Joint Infections Caused by Enterococci Have Poor Outcomes. J Arthroplasty. 2017;32(3):933–947. doi:10.1016/j.arth.2016.09.017. Duijf S V, Vos FJ, Meis JF, Goosen JH. Debridement, antibiotics and implant retention in early postoperative infection with Enterococcus sp. Clin Microbiol Infect. 2015;21(5):e41–e42. doi:10.1016/j.cmi.2015.01.006. Tornero E, Soriano A. Prosthetic joint infection due to Enterococcus sp treated with debridement, antibiotics and retention of the implant (DAIR) Clin Microbiol Infect. 2015;21(5):e43–e44. doi:10.1016/j.cmi.2015.01.012. Lora-Tamayo J, Murillo O, Iribarren JA. et al. A large multicenter study of methicillin-susceptible and methicillin-resistant staphylococcus aureus prosthetic joint infections managed with implant retention. Clin Infect Dis. 2013;56(2):182–194. doi:10.1093/cid/cis746. Zürcher-Pfund L, Uçkay I, Legout L, Gamulin A, Vaudaux P, Peter R. Pathogen-driven decision for implant retention in the management of infected total knee prostheses. Int Orthop. 2013;37(8):1471–1475. doi:10.1007/s00264-013-1923-4. [PMC free article] Euba G, Lora-Tamayo J, Murillo O. et al. Pilot study of ampicillin-ceftriaxone combination for treatment of orthopedic infections due to Enterococcus faecalis. Antimicrob Agents Chemother. 2009;53(10):4305–4310. doi:10.1128/AAC.00444-09. [PMC free article] Baddour LM, Wilson WR, Bayer AS. et al. Infective endocarditis in adults: Diagnosis, antimicrobial therapy, and management of complications: A scientific statement for healthcare professionals from the American Heart Association. Circulation. 2015;132(15):1435–1486. doi:10.1161/CIR.0000000000000296. Holmberg A, Mörgelin M, Rasmussen M. Effectiveness of ciprofloxacin or linezolid in combination with rifampicin against Enterococcus faecalis in biofilms. J Antimicrob Chemother. 2012;67(2):433–439. doi:10.1093/jac/dkr477. Holmberg A, Rasmussen M. Antibiotic regimens with rifampicin for treatment of Enterococcus faecium in biofilms. Int J Antimicrob Agents. 2014;44(1):78–80. doi:10.1016/j.ijantimicag.2014.03.008.